Coronavirus Update: Another Vaccine Disappointment For GSK
Plus: UK Increases Order From Valneva
After suffering a setback in its joint venture with Sanofi, GlaxoSmithKline has been dropped by another vaccine partner, Clover, as it looks for the best adjuvant for its COVID-19 candidate.
You may also be interested in...
Coronavirus Update: With New Data, Don’t Count J&J Out Yet
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.